PharmAla and Mt. Sinai Health System Collaboration
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a cutting-edge biotechnology firm, is thrilled to share its recent achievement in partnering with Mt. Sinai Health System for the supply of its GMP LaNeo™ MDMA. This partnership marks a significant transition into a new chapter of clinical research, reinforcing the company’s commitment to advancing medical treatments.
Commitment to Quality in Clinical Trials
In a statement from Nicholas Kadysh, CEO of PharmAla Biotech, he expressed optimism regarding the collaboration, saying, “We’re looking forward to supporting the team at Mt. Sinai Health System with a high-quality clinical trial drug product.” This environment, complemented by Mt. Sinai’s top-tier researchers and state-of-the-art facilities, positions PharmAla at the forefront of MDMA-assisted therapy initiatives.
Innovative Tools for Researchers
PharmAla is offering researchers access to new resources that streamline their operations. By visiting their dedicated portal, clinical scientists can directly examine drug product quality information, ensuring transparency and efficiency in their work. PharmAla strives to support its research clientele in aligning their clinical trial registrations and IRB approvals with the LaNeo MDMA Chemistry, Manufacturing, and Control package.
Termination of Agreement with CCrest Labs
In a recent development, PharmAla and CCrest Labs have mutually decided to terminate their existing supply agreement. Initially contracted in 2022 for the distribution of MDMA under the Special Access Program, PharmAla will transition to other dependable contracted distributors to fulfill its commitments moving forward.
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc. is dedicated to the research, development, and production of MDXX class molecules, notably MDMA. The company has designed its operations not only to address the increasing demand for generic, clinical-grade MDMA but also to foster innovation in novel drug formulations. As the only firm supplying clinical-grade MDMA for patient treatment beyond clinical trials, PharmAla is genuinely a leader in the industry.
Research and Development Initiatives
The R&D sector of PharmAla has made substantial strides, completing proof-of-concept studies across various intellectual property families, including ALA-002, their leading drug candidate. The organization prides itself on establishing strong relationships with regulatory bodies, illustrating that successful advancements in the psychedelics field come from collaborative efforts.
Future Prospects in MDMA Research
As PharmAla continues to pioneer its development efforts, the landscape for MDMA-assisted therapies is evolving. The collaboration with Mt. Sinai symbolizes a broader trend where high-quality clinical trials play a critical role in establishing the therapeutic potential of MDMA in various medical contexts. PharmAla is keen to be a driving force in this transformation, leading with integrity and commitment to excellence.
Contact Information for Inquiries
For more information, interested parties can reach out to Nicholas Kadysh, Chief Executive Officer of PharmAla Biotech Holdings Inc., through the following channels:
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is PharmAla’s primary focus?
PharmAla is primarily focused on the research, development, and manufacturing of MDXX class molecules, including LaNeo™ MDMA.
What recent development has PharmAla announced?
PharmAla has announced its partnership with Mt. Sinai Health System to supply LaNeo™ MDMA for clinical trials.
Who is the CEO of PharmAla Biotech?
The current CEO of PharmAla Biotech Holdings Inc. is Nicholas Kadysh.
What tools does PharmAla provide for researchers?
PharmAla provides a dedicated portal for researchers to access drug product quality information securely.
What is PharmAla’s commitment to regulatory relationships?
PharmAla prioritizes building strong, cooperative relationships with regulatory bodies to ensure successful developments in the psychedelics industry.
